Description: Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Home Page: kronosbio.com
KRON Technical Analysis
1300 South El Camino Real
San Mateo,
CA
94402
United States
Phone:
650 781 5200
Officers
| Name | Title |
|---|---|
| Dr. Norbert W. Bischofberger Ph.D. | Pres, CEO & Director |
| Mr. Joshua A. Kazam | Co-Founder & Director |
| Dr. Yasir B. Al-Wakeel BCh, BM, MA | CFO & Head of Corp. Devel. |
| Ms. Barbara A. Kosacz J.D. | COO, Sec. & Gen. Counsel |
| Dr. Christopher Dinsmore Ph.D. | Chief Scientific Officer |
| Dr. Jorge F. DiMartino M.D., Ph.D. | Chief Medical Officer & Exec. VP of Clinical Devel. |
| Stephanie Yao | Exec. Director of Investor Relations & Corp. Communications |
| Ms. Marni Kottle | Sr. VP of Corp. Communications & Investor Relations |
| Mr. Charles Lin Ph.D. | Sr. VP of Biology |
| Dr. Elizabeth A. Olek D.O., M.P.H. | Sr. VP of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4187 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |